<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799290</url>
  </required_header>
  <id_info>
    <org_study_id>R15034</org_study_id>
    <nct_id>NCT02799290</nct_id>
  </id_info>
  <brief_title>Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing</brief_title>
  <official_title>The Effect of Adipose Tissue Extract and Platelet-rich Plasma on Split-thickness Donor Site Wound Healing. A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adipose Tissue Extract (ATE) has been found to be an autologous source of growth factors with&#xD;
      proven in vitro angiogenic and adipogenic properties.It is obtained by a simple lipoaspirate&#xD;
      procedure. We sought to compare the effect of ATE with another known source, platelet-rich&#xD;
      plasma to compare the wound healing characteristics on skin graft donor sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled 24 participants with an indication for skin graft. Two or more&#xD;
      split-thickness grafts are harvested per patient, one serving as control and the other as&#xD;
      experimental. The experimental sites were covered with either autologous PRP gel or ATE&#xD;
      prepared in the OR, which was selected in an unblinded manner due to surgical theater&#xD;
      convenience. However, donor sites were randomized through a computer generator. Covered with&#xD;
      a semiocclusive film, wounds were separated and followed up on days 3,5,7,10,14 for wound&#xD;
      healing and 30 and 60 for scar evaluation. Digital photography and specto-photocutometry was&#xD;
      employed to know the hemoglobin and melanin content of the wounds, and custom-made software&#xD;
      was used to calculate the percentage of wound re-epithelialization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Re-epithelization</measure>
    <time_frame>30 days</time_frame>
    <description>observational-digital photography with specialized custom-made software</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scar Properties</measure>
    <time_frame>30 and 60 days</time_frame>
    <description>Vancouver Manchester modified scar scale Minimum value 0 maximum value 14 Higher scores mean worse outcome (Scale analyzes 5 wound characteristics in a numeric scale, where 0 is the best scar outcome and 14 the worst. These characteristics are wound: pigmentation, height, vascularity, contour, texture and brightness.) See scale below Vascularity Normal 0 Pink 1 Red 2 Purple 3 Pigmentation Normal 0 Hypopigmentation 1 Hyperpigmentation 2&#xD;
Height Flat 0 Depressed1 Elevated 2 Matte vs. shine Shine 0 Matte 1 Contour Forms part of the adjacent skin 0 Small indentation or invagination 1 Hypertrophic 2 Keloid 3 Texture Normal 0 Barely palpable 1 Rough 2 Indented 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenated Hemoglobin</measure>
    <time_frame>day 30 and 60</time_frame>
    <description>Spectophotocutometry measurements with specialized digital camera and software analysis measured in estimated concentration changes (ECC). ECC is a ratio of light reflected hemoglobin chromofore on a special diode light camera. The ratio is between the scar and the adjacent normal skin and is an arbitrary scale previously published. From 0 to 1, where 1 are values closest to the adjacent healthy unscarred skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanin Concentration in Wound</measure>
    <time_frame>day 30 and 60</time_frame>
    <description>Melanin concentration measured by spectophotocutometry and analyzed by computer software and represented in estimated concentration changes (ECC), as explained above is an arbitrary ratio between the light absorbance between the scar and the adjacent healthy (unscarred skin) for the melanin chromofore.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Wound Healing Disturbance of</condition>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADIPOSE TISSUE EXTRACT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose Tissue extract application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLATELET-RICH PLASMA GEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLATELET RICH PLASMA GEL APPLICATION</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADIPOSE TISSUE EXTRACT</intervention_name>
    <description>Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
    <arm_group_label>ADIPOSE TISSUE EXTRACT</arm_group_label>
    <other_name>ATE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLATELET-RICH PLASMA GEL</intervention_name>
    <description>Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
    <arm_group_label>PLATELET-RICH PLASMA GEL</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  donor site indication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosupressive states&#xD;
&#xD;
          -  terminal renal insufficiency&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  coagulation dyscrasias&#xD;
&#xD;
          -  active infection in donor site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timo Ylikomi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jenny Lopez, Ilkka Kaartinen</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <results_reference>
    <citation>Sarkanen JR, Kaila V, Mannerström B, Räty S, Kuokkanen H, Miettinen S, Ylikomi T. Human adipose tissue extract induces angiogenesis and adipogenesis in vitro. Tissue Eng Part A. 2012 Jan;18(1-2):17-25. doi: 10.1089/ten.TEA.2010.0712. Epub 2011 Oct 4.</citation>
    <PMID>21902602</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarkanen JR, Ruusuvuori P, Kuokkanen H, Paavonen T, Ylikomi T. Bioactive acellular implant induces angiogenesis and adipogenesis and sustained soft tissue restoration in vivo. Tissue Eng Part A. 2012 Dec;18(23-24):2568-80. doi: 10.1089/ten.TEA.2011.0724. Epub 2012 Aug 17.</citation>
    <PMID>22738319</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <results_first_submitted>October 26, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University</investigator_affiliation>
    <investigator_full_name>Jenny Lopez</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>If required, individual data can be shown</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CONTROL</title>
          <description>No treatment</description>
        </group>
        <group group_id="P2">
          <title>ADIPOSE TISSUE EXTRACT</title>
          <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
        </group>
        <group group_id="P3">
          <title>PLATELET-RICH PLASMA GEL</title>
          <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Wound healing characteristics of donor sites in time</population>
      <group_list>
        <group group_id="B1">
          <title>CONTROL</title>
          <description>No intervention</description>
        </group>
        <group group_id="B2">
          <title>ADIPOSE TISSUE EXTRACT</title>
          <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
        </group>
        <group group_id="B3">
          <title>PLATELET-RICH PLASMA GEL</title>
          <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="16.82"/>
                    <measurement group_id="B2" value="56.07" spread="16.57"/>
                    <measurement group_id="B3" value="62.45" spread="17.23"/>
                    <measurement group_id="B4" value="59" spread="16.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Re-epithelization</title>
        <description>observational-digital photography with specialized custom-made software</description>
        <time_frame>30 days</time_frame>
        <population>Measured as a whole per group as mean and standard deviation of group and not participant healing.</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>ADIPOSE TISSUE EXTRACT</title>
            <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
          </group>
          <group group_id="O3">
            <title>PLATELET-RICH PLASMA GEL</title>
            <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Re-epithelization</title>
          <description>observational-digital photography with specialized custom-made software</description>
          <population>Measured as a whole per group as mean and standard deviation of group and not participant healing.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.34"/>
                    <measurement group_id="O2" value="10.27"/>
                    <measurement group_id="O3" value="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scar Properties</title>
        <description>Vancouver Manchester modified scar scale Minimum value 0 maximum value 14 Higher scores mean worse outcome (Scale analyzes 5 wound characteristics in a numeric scale, where 0 is the best scar outcome and 14 the worst. These characteristics are wound: pigmentation, height, vascularity, contour, texture and brightness.) See scale below Vascularity Normal 0 Pink 1 Red 2 Purple 3 Pigmentation Normal 0 Hypopigmentation 1 Hyperpigmentation 2&#xD;
Height Flat 0 Depressed1 Elevated 2 Matte vs. shine Shine 0 Matte 1 Contour Forms part of the adjacent skin 0 Small indentation or invagination 1 Hypertrophic 2 Keloid 3 Texture Normal 0 Barely palpable 1 Rough 2 Indented 3</description>
        <time_frame>30 and 60 days</time_frame>
        <population>Modified Vancouver/Manchester scar scale at 30 days</population>
        <group_list>
          <group group_id="O1">
            <title>CONTROL ATE</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>ADIPOSE TISSUE EXTRACT</title>
            <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
          </group>
          <group group_id="O3">
            <title>PLATELET-RICH PLASMA GEL</title>
            <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
          </group>
          <group group_id="O4">
            <title>CONTROL PRP</title>
            <description>No treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Scar Properties</title>
          <description>Vancouver Manchester modified scar scale Minimum value 0 maximum value 14 Higher scores mean worse outcome (Scale analyzes 5 wound characteristics in a numeric scale, where 0 is the best scar outcome and 14 the worst. These characteristics are wound: pigmentation, height, vascularity, contour, texture and brightness.) See scale below Vascularity Normal 0 Pink 1 Red 2 Purple 3 Pigmentation Normal 0 Hypopigmentation 1 Hyperpigmentation 2&#xD;
Height Flat 0 Depressed1 Elevated 2 Matte vs. shine Shine 0 Matte 1 Contour Forms part of the adjacent skin 0 Small indentation or invagination 1 Hypertrophic 2 Keloid 3 Texture Normal 0 Barely palpable 1 Rough 2 Indented 3</description>
          <population>Modified Vancouver/Manchester scar scale at 30 days</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.13" spread="2.795"/>
                    <measurement group_id="O2" value="4.86" spread="2.13"/>
                    <measurement group_id="O3" value="6.46" spread="2.53"/>
                    <measurement group_id="O4" value="6.85" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="2.8"/>
                    <measurement group_id="O2" value="2.4" spread="2.2"/>
                    <measurement group_id="O3" value="3.23" spread="2.4"/>
                    <measurement group_id="O4" value="5.69" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenated Hemoglobin</title>
        <description>Spectophotocutometry measurements with specialized digital camera and software analysis measured in estimated concentration changes (ECC). ECC is a ratio of light reflected hemoglobin chromofore on a special diode light camera. The ratio is between the scar and the adjacent normal skin and is an arbitrary scale previously published. From 0 to 1, where 1 are values closest to the adjacent healthy unscarred skin.</description>
        <time_frame>day 30 and 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>ADIPOSE TISSUE EXTRACT</title>
            <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
          </group>
          <group group_id="O3">
            <title>PLATELET-RICH PLASMA GEL</title>
            <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
          </group>
          <group group_id="O4">
            <title>CONTROL PRP</title>
            <description>no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenated Hemoglobin</title>
          <description>Spectophotocutometry measurements with specialized digital camera and software analysis measured in estimated concentration changes (ECC). ECC is a ratio of light reflected hemoglobin chromofore on a special diode light camera. The ratio is between the scar and the adjacent normal skin and is an arbitrary scale previously published. From 0 to 1, where 1 are values closest to the adjacent healthy unscarred skin.</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.18"/>
                    <measurement group_id="O2" value="0.20" spread="0.22"/>
                    <measurement group_id="O3" value="0.24" spread="0.31"/>
                    <measurement group_id="O4" value="0.28" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.30"/>
                    <measurement group_id="O2" value="0.19" spread="0.11"/>
                    <measurement group_id="O3" value="0.09" spread="0.17"/>
                    <measurement group_id="O4" value="0.01" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Melanin Concentration in Wound</title>
        <description>Melanin concentration measured by spectophotocutometry and analyzed by computer software and represented in estimated concentration changes (ECC), as explained above is an arbitrary ratio between the light absorbance between the scar and the adjacent healthy (unscarred skin) for the melanin chromofore.</description>
        <time_frame>day 30 and 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CONTROL</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>ADIPOSE TISSUE EXTRACT</title>
            <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
          </group>
          <group group_id="O3">
            <title>PLATELET-RICH PLASMA GEL</title>
            <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
          </group>
          <group group_id="O4">
            <title>PRP Control</title>
            <description>no treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Melanin Concentration in Wound</title>
          <description>Melanin concentration measured by spectophotocutometry and analyzed by computer software and represented in estimated concentration changes (ECC), as explained above is an arbitrary ratio between the light absorbance between the scar and the adjacent healthy (unscarred skin) for the melanin chromofore.</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAY 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                    <measurement group_id="O2" value="0.03" spread="0.03"/>
                    <measurement group_id="O3" value="0.03" spread="0.03"/>
                    <measurement group_id="O4" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAY 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="0.02" spread="0.04"/>
                    <measurement group_id="O3" value="0.02" spread="0.02"/>
                    <measurement group_id="O4" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CONTROL</title>
          <description>No treatment</description>
        </group>
        <group group_id="E2">
          <title>ADIPOSE TISSUE EXTRACT</title>
          <description>Adipose Tissue extract application&#xD;
ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration</description>
        </group>
        <group group_id="E3">
          <title>PLATELET-RICH PLASMA GEL</title>
          <description>PLATELET RICH PLASMA GEL APPLICATION&#xD;
PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ilkka Kaartinen</name_or_title>
      <organization>Tampere University Hospital</organization>
      <phone>505687096</phone>
      <email>ilkka.kaartinen@pshp.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

